SciELO - Scientific Electronic Library Online

 
vol.46 número3Inclusión de omalizumab en un protocolo de desensibilización de trastuzumab índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Farmacia Hospitalaria

versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343

Farm Hosp. vol.46 no.3 Toledo Mai./Jun. 2022  Epub 11-Jul-2022

https://dx.doi.org/10.7399/fh.13281 

Corrige o artigo: 10.7399/fh.11628

ERRATUM

Erratum found in «Farmacia Hospitalaria. 2021;45(3):126-34»

Eduardo Tejedor-Tejada1  , Pablo Nieto-Guindo1  , Javier Tejedor-Tejada2  , Estrella Martínez-Velasco1  , Araceli Gómez-Sánchez3 

1Department of Hospital Pharmacy, Hospital Universitario Torrecárdenas, Almería. Spain

2Department of Digestive Surgery, Hospital Universitario Río Hortega, Valladolid. Spain

3Department of Hospital Pharmacy, Hospital Costa del Sol, Marbella. Spain

An error has been detected in the English version of the article «A guide for the administration of oral antineoplastic in patients with swallowing disorders», published in Farm Hosp. 2021;46(3):126-34:

In Table 1. Line 1 relative to ABIRATERONE film-coated tablets (Zytiga®).

Where it says:

The manufacturer recommends crushing or dissolving the product due to a potential decrease in efficacy.

Have to say:

The manufacturer no recommends crushing or dissolving the product due to a potential decrease in efficacy.

Received: April 25, 2022; Accepted: April 30, 2022; pub: May 05, 2022

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License